These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8471777)

  • 1. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.
    Rosendaal FR; Nieuwenhuis HK; van den Berg HM; Heijboer H; Mauser-Bunschoten EP; van der Meer J; Smit C; Strengers PF; Briët E
    Blood; 1993 Apr; 81(8):2180-6. PubMed ID: 8471777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A.
    Mauser-Bunschoten EP; Rosendaal FR; Nieuwenhuis HK; Roosendaal G; Briët E; van den Berg HM
    Thromb Haemost; 1994 Jun; 71(6):703-6. PubMed ID: 7974335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Leebeek FWG; Escuriola-Ettingshausen C; Hermans C; Keenan R; Astermark J; Male C; Peerlinck K; le Cessie S; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1422-1429. PubMed ID: 28440011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
    Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
    N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors.
    Sawamoto Y; Prescott R; Zhong D; Saenko EL; Mauser-Bunschoten E; Peerlinck K; van den Berg M; Scandella D
    Thromb Haemost; 1998 Jan; 79(1):62-8. PubMed ID: 9459325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract]   [Full Text] [Related]  

  • 14. [Factor VIII inhibitor in multitransfused hemophiliacs. A finding of varying therapeutic consequences].
    Ly B; Evensen SA; Stavem P
    Tidsskr Nor Laegeforen; 1977 Apr; 97(12):554-6, 8. PubMed ID: 854906
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C.
    Mauser-Bunschoten EP; Damen M; Reesink HW; Roosendaal G; Chamuleau RA; van den Berg HM
    Ann Intern Med; 1996 Aug; 125(4):297-9. PubMed ID: 8678393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy.
    Chen AC; Cai X; Li C; Khoryati L; Gavin MA; Miao CH
    Front Immunol; 2020; 11():638. PubMed ID: 32411127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.
    Kempton CL; Soucie JM; Abshire TC
    J Thromb Haemost; 2006 Dec; 4(12):2576-81. PubMed ID: 17002659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of anti-factor VIII antibodies.
    Blatt PM; White GC; McMillan CW; Roberts HR
    Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.